New agents in relapsed/refractory Hodgkin's lymphoma

Biasoli, Irène; Spector, Nelson

doi:10.1016/j.bjhh.2017.05.003

Cited by 2 publications

(2 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the early 1970s the incidence of non-Hodgkin lymphoma (NHL) has increased by almost 60% in both men and women, blacks and whites, making it, along with malignant melanoma and lung cancer in women, one of the most rapidly increasingly diagnosed malignancies in the industrialized world [9]. Two new chemotherapeutic agents, vinorelbine and gemcitabine, have shown encouraging early results in the treatment of heavily pre-treated relapsed or refractory lymphoma when used as single agents, with responses of between 20 and 47% [10]. Vinorelbine is a semisynthetic vinca alkaloid whereas gemcitabine is a novel nucleoside analogue of deoxycytidine, both can be safely given in the outpatient setting through short i.e.…”

Section: Discussionmentioning

confidence: 99%

Gemcitabine Plus Vinorelbine for Refractory or Relapsing Non-Hodgkin Lymphoma: Response Rate and Survival

Elbary

Saed

Hussein

et al. 2021

JAMMR

View full text Add to dashboard Cite

Background: Two chemotherapeutic agents, vinorelbine and gemcitabine, have shown encouraging early results in the treatment of heavily pre-treated relapsed or refractory lymphoma when used as single agents, with responses of between 20 and 47%. This work aimed to evaluate the role of gemcitabine and vinorelbine in the treatment of relapsed and /or refractory aggressive Non-Hodgkin Lymphoma (NHL) as regard response rate, survival analysis. Methods: This prospective study was conducted on 20 patients who had relapsed and /or refractory NHL and treated with a minimum follow of 6 months. All patients were subjected to full clinical examination, laboratory and radiological study. Vinorelbine, Gemcitabine, dexamethasone, filgrastim (VGF) was administrated, On days 1 and 8, patients received vinorelbine 25 mg/m2, Gemcitabine 1000 mg/m2 and Dexamethasone 16mg/m2 I.V, On day 9, they received peg-filgrastim 6 mg subcutaneously, Patients received 4 cycles of VGF, Assessment was performed after 4th cycle of treatment and according to response during follow up period, the patient received 2 more cycles with minimum follow up 6 months and/or PET-CT was done in all patients to evaluate response rate. Results: Regarding status; 60 % of patients were relapsed and 40% of them were refractory. Regarding line therapy: all patients were treated with 1st line protocol of Rituxan/Rituximab-Cyclophosphamide-Hydroxydaunorubicin-Oncovin-Prednisone regimen (R-CHOP), and 4 of them had been treated with 2nd line chemotherapy of Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE). So 80% of patients received VGF chemotherapy as 2nd line, while 20% of them received it as the 3rd line. And there was no statistical difference between relapsed and refractory groups regarding lines of VGF chemotherapy. Regarding the toxicity of VGF (toxicity criteria as defined by Chesson and WHO); 50% of patients complicated with grade III anaemia, 50% of patients complicated with grade III neutropenia, 60% of patients complicated with grade III thrombocytopenia, 20% of patients complicated with grade II GIT upset, 40% of patients complicated grade II thrombophlebitis and 40% of patients complicated with grade II neurotoxicity. Conclusions: VGF shows substantial activity in relapsed or refractory aggressive NHL. The regimen is generally well-tolerated, but haematological toxicity is common.

show abstract

Section: Discussionmentioning

confidence: 99%

Gemcitabine Plus Vinorelbine for Refractory or Relapsing Non-Hodgkin Lymphoma: Response Rate and Survival

Elbary

Saed

Hussein

et al. 2021

JAMMR

View full text Add to dashboard Cite

show abstract

“… 8 Standard treatment in these cases is based on autologous hematopoietic stem cell transplantation (HSCT) or high doses of chemotherapy, with the PFS reaching 30–50% in patients with relapsed disease and 20–40% in patients with refractory HL. 9 , 10 , 11 …”

Section: Introductionmentioning

confidence: 99%

High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center

Jaime‐Pérez

Gamboa-Alonso

Padilla-Medina

et al. 2017

Revista Brasileira de Hematologia e Hemoterapia

View full text Add to dashboard Cite

BackgroundReports dealing with clinical outcomes of classical Hodgkin's lymphoma in low- to middle-income countries are scarce and response to therapy is poorly documented. This report describes the characteristics and clinical outcomes of patients with classical Hodgkin's lymphoma from a single institution in Latin America.MethodA retrospective study was conducted over ten years of patients with classical Hodgkin's lymphoma treated at a referral center. Progression-free and overall survival rates were estimated by Kaplan–Meier analysis. The univariate Cox regression model was used to estimate associations between important variables and clinical outcomes.Main resultsOne hundred and twenty-eight patients were analyzed. The mean age was 28.5 years. The five-year progression-free and overall survival were 37.3% and 78.9%, respectively. Of the whole group, 55 (43%) were primary refractory cases. Only 39/83 (47%) patients with advanced disease vs. 34/45 (75.6%) in early stages (p-value = 0.002) achieved complete remission. Those with advanced disease had a five-year overall survival of 68.7% vs. 91.8% for early disease (p-value = 0.132). Thirty-one patients relapsed (24.2%) and 20 (64.5%) received a transplant. The hazard ratio for progression with bone marrow infiltration was 2.628 (p-value = 0.037). For death, an International Prognostic Score ≥4 had a hazard ratio of 3.355 (p-value = 0.050) in univariate analysis. Two-thirds of classical Hodgkin's lymphoma patients diagnosed at advanced stages had a low progression-free survival but an overall survival similar to high-income countries.ConclusionPatients diagnosed with classical Hodgkin's lymphoma in Northeastern Mexico had a significantly low progression-free survival rate and presented with advanced disease, underscoring the need for earlier diagnosis and improved contemporary therapeutic strategies in these mainly young productive-age Hodgkin's lymphoma patients.

show abstract

New agents in relapsed/refractory Hodgkin's lymphoma

Cited by 2 publications

References 49 publications

Gemcitabine Plus Vinorelbine for Refractory or Relapsing Non-Hodgkin Lymphoma: Response Rate and Survival

Gemcitabine Plus Vinorelbine for Refractory or Relapsing Non-Hodgkin Lymphoma: Response Rate and Survival

High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center

Contact Info

Product

Resources

About